Partnerships, Licensing, Investments and M&A Deals and Trends for February 2019 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare ...

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2019 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, February 2019 12

2.2.1 Danaher to Acquire Biopharma Business from General Electric for USD21.4 Billion 12

2.2.2 Takeda Pharma Files Shelf Registration Statement for Public Offering of Hybrid Bonds Due 2079 for USD4.52 Billion 13

2.2.3 Roche to Acquire Spark Therapeutics 13

2.2.4 GlaxoSmithKline and Merck Enter into Co-Development Agreement 14

2.2.5 Abpro and Jiangsu Chia-tai Tianqing Pharma Enter into Development Agreement 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 2019 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 2019 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, February 2019 17

3.1.1 Top M&A Deals in February 2019 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2018 – February 2019 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2019 20

3.2.1 Top Equity Offering Deals in February 2019 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2018 – February 2019 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2019 23

3.3.1 Top PE/VC Deals in February 2019 24

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 2019 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2019 26

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016–February 2019 28

3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016–February 2019 29

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2019 30

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2018 – February 2019 31

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2019 32

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 2019 33

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 34

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2018 – February 2019 35

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2018 – February 2019 36

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 37

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2019 39

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2019 39

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2019 40

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2018 – February 2019 41

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2018 – February 2019 42

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2018 – February 2019 44

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2018 – February 2019 46

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 2019 47

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 2019 48

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2019 48

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 49

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2019 49

5.1.1 Oncology – Deals of the Month 50

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2019 52

5.2.1 Central Nervous System – Deals of the Month 53

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2019 55

5.3.1 Infectious Diseases – Deals of the Month 56

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2019 58

5.4.1 Cardiovascular – Deals of the Month 59

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2019 60

5.5.1 Immunology – Deal of the Month 61

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, February 2019 63

5.6.1 Gastrointestinal – Deals of the Month 64

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, February 2019 66

5.7.1 Metabolic Disorders – Deals of the Month 67

6 Deal Summary by Geography 69

6.1 Pharmaceuticals & Healthcare, North America Deals, February 2019 69

6.1.1 North America – Deals of the Month 70

6.2 Pharmaceuticals & Healthcare, Europe, Deals, February 2019 73

6.2.1 Europe – Deals of the Month 74

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2019 76

6.3.1 Asia-Pacific – Deals of the Month 77

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2019 79

6.4.1 Rest of the World – Deals of the Month 80

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 82

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2018 – February 2019 82

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2018 – February 2019 84

8 Further Information 85

8.1 Methodology 85

8.2 About GlobalData 86

8.3 Contact Us 86

8.4 Disclosure information 86

8.5 Disclaimer 87

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 ...

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, February 2019 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 2019 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 2019 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2018 – February 2019 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 2019 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 22

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 24

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 2019 24

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2018 – February 2019 25

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), February 2019 27

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 28

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2018 – February 2019 29

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 30

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 31

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 32

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 2019 33

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 34

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2018 – February 2019 36

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2018 – February 2019 38

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 39

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 40

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 41

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 2019 42

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2018 – February 2019 45

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2019 47

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, February 2019 47

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 2019 48

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 2019 48

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 50

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 53

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 56

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 59

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 61

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 64

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 67

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 70

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 74

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 77

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 80

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 83

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 84

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 10

Figure ...

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), February 2019 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), February 2019 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2018 – February 2019 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 23

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2018 – February 2019 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), February 2019 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), February 2019 27

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 28

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 30

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 31

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 32

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2018 – February 2019 35

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2018 – February 2019 36

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 37

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 39

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 40

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 41

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2018 – February 2019 42

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, September 2018 – February 2019 44

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), September 2018 – February 2019 45

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 2019 46

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 49

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 52

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 55

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 58

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 60

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 63

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 66

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 69

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 73

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 76

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 79

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 82

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2018 – February 2019 84

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

GlobalData has been a tremendous source for us

  Jabil Circuit